{
    "eid": "2-s2.0-85139343905",
    "title": "Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination",
    "cover-date": "2022-10-15",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "AZD1222",
        "COVID-19",
        "mRNA vaccine",
        "omicron",
        "third dose"
    ],
    "authors": [
        "Suvichada Assawakosri",
        "Sitthichai Kanokudom",
        "Nungruthai Suntronwong",
        "Chompoonut Auphimai",
        "Pornjarim Nilyanimit",
        "Preeyaporn Vichaiwattana",
        "Thanunrat Thongmee",
        "Thaneeya Duangchinda",
        "Warangkana Chantima",
        "Pattarakul Pakchotanon",
        "Donchida Srimuan",
        "Thaksaporn Thatsanatorn",
        "Sirapa Klinfueng",
        "Ritthideach Yorsaeng",
        "Natthinee Sudhinaraset",
        "Nasamon Wanlapakorn",
        "Juthathip Mongkolsapaya",
        "Sittisak Honsawek",
        "Yong Poovorawan"
    ],
    "citedby-count": 33,
    "ref-count": 43,
    "ref-list": [
        "Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape",
        "China's COVID vaccines have been crucial - now immunity is waning",
        "Effectiveness of an Inactivated SARS-CoV-2 vaccine in Chile",
        "Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study [preprint]",
        "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey",
        "Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study",
        "Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials",
        "Waning immunity after the BNT162b2 vaccine in Israel",
        "Emerging SARS-CoV-2 variants of concern and potential intervention approaches",
        "Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants",
        "The global epidemic of the SARS-CoV-2 delta variant, key spike mutations and immune escape",
        "Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant [preprint]",
        "CoronaVac induces lower neutralising activity against variants of concern than natural infection",
        "Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum",
        "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies",
        "Characterization of the novel SARS-CoV-2 Omicron (B. 1.1. 529) variant of concern and its global perspective",
        "Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections or vaccinees",
        "T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals",
        "Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals",
        "Homologous and heterologous vaccine boost strategies for humoral and cellular immunologic coverage of the SARS-CoV-2 omicron variant",
        "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial",
        "Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial",
        "Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine",
        "Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2",
        "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial",
        "An mRNA vaccine against SARS-CoV-2 - preliminary report",
        "Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera",
        "Distinct antibody, and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination",
        "Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study",
        "Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection",
        "Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7",
        "Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection",
        "Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost",
        "Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies [preprint]",
        "Receptor binding and escape from Beta antibody responses drive Omicron-B.1.1.529 evolution [preprint]",
        "Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity",
        "SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients",
        "SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63",
        "SARS-CoV-2-specific T cells in infection and vaccination",
        "Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021",
        "Effectiveness of homologous and heterologous booster shots for an inactivated SARS-CoV-2 vaccine: A Large-Scale Observational Study [preprint]"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Oxford",
            "@id": "60026851",
            "affilname": "University of Oxford",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026851",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60011947",
            "affilname": "Thailand National Center for Genetic Engineering and Biotechnology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011947",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Oxford",
            "@id": "60008936",
            "affilname": "Nuffield Department of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60008936",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "101823394",
            "affilname": "Royal Society of Thailand",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101823394",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Center of Excellence in Clinical Virology",
        "King Chulalongkorn Memorial Hospital",
        "Chulalongkorn University",
        "National Research Council of Thailand",
        "Health Systems Research Institute",
        "National Center for Genetic Engineering and Biotechnology"
    ]
}